Celltrion's CT-P10 (rituximab): Revenue Forecast, 2013-20234.2.6 Boehringer Ingelheim's BI695501 (adalimumab): Revenue Forecast, 2013-20234.2.7 Fujifilm Kyowa Kirin Biologics' adalimumab: Revenue Forecast, 2013-20234.2.8 Fujifilm Kyowa Kirin Biologics' bevacizumab: Revenue Forecast, 2013-20234.2.9 Celltrion's CT-P06 (trastuzumab): Revenue Forecast, 2013-20234.2.10 Biocon's Bmab200 (trastuzumab): Revenue Forecast, 2013-20234.2.11 BIOCAD's BCD-022 (trastuzumab): Revenue Forecast, 2013-20234.2.12 Isu Abxis' Clotinab (abciximab): Revenue Forecast, 2013-20234.2.13 Reliance Life Sciences' R-TPR-019 (abciximab): Revenue Forecast, 2013-2023
5. Leading National Markets for Biosimilar Monoclonal Antibodies, 2013-2023
5.1 What Were the Leading National Markets for Biosimilar Monoclonal Antibody Development in 2012?
5.2 What Were the Leading National Markets for Sales of Biosimilar Monoclonal Antibodies in 2012?
5.3 Which Markets Will Grow Fastest to 2023?
5.4 Market Shares of the Leading National Markets: All Set to Change, 2013-2023
5.5 The Outlook for Biosimilar MAbs in the US, 2013-2023
5.5.1 When Are the Final FDA Biosimilar Guidelines Expected?
5.5.2 Legal Challenges for Biosimilars in the US
5.5.3 State Regulation of Biosimilar Substitution
5.5.4 The US Biosimilar MAb Market: Revenue Forecast, 2013-2023
5.6 The Outlook for Monoclonal Antibody Biosimilars in the EU, 2013-2023
5.6.1 The EU Led the World in Biosimilar Regulation
5.6.2 Updating Biosimilar Regulation: Guidelines for the Specific Approval of Biosimilar MAbs
5.6.3 EMA Simplifies Biosimilar Development in the EU
5.6.4 Biosimilar MAbs: EU Launch in 2014?
5.6.5 Germany: Set to Become the Largest National Market for Biosimilar MAbs in the EU
5.6.6 France: Will the Uptake of Biosimilar MAbs Be Restricted?
5.6.7 UK: Drug Uptake Will Be HighPage: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 Related medicine technology :1
. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars2
. Biosimilars in Emerging Economies - Advanced Recombinant Technology Platforms and Low Cost Manufacturing Put India and China at a Strategic Advantage in Biosimilar Production3
. Novation Supports New Development in the U.S. Biosimilar Pharmaceuticals Market4
. ASBM Survey Reveals Key Safety Concern Associated with Biosimilar Naming; Urges Distinct Naming Requirement5
. Reliance Pharmaceuticals: Biosimilars Company Analysis6
. Oncobiologics and Boston Oncology Team Up to Deliver Biosimilar Therapies for Cancer and Immune Disease to Middle East and North African Markets7
. Ground Zero Pharmaceuticals, Inc. (GZP) Announces Enhanced Biosimilars and Personalized Medicine Initiatives for its Clients8
. Active Pharmaceutical Ingredients (API) Market in the Americas to 2017 - Shift Towards Generics and Biosimilars as South and Central America Emerges as a Key Growth Region9
. Musculoskeletal Network Launches Special Coverage of FDA Biosimilars Policy10
. Cell Culture - Rising Demand for Biologics and Growing Visibility of Approval Pathway for Biosimilars will Create Growth Opportunities11
. Global Biosimilars: A return to optimism?